ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
ImmunoGen, Inc. (IMGN) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2022 | 17.98 M | -259,894,000 | 193.11 M | 348.94 M | 275.14 M |
| 2021 | 17.98 M | -259,894,000 | 193.11 M | 348.94 M | 275.14 M |
| 2020 | 22.5 M | -269,966,000 | 265.5 M | 355.07 M | 293.86 M |
| 2019 | 27.25 M | -149,378,000 | 311.78 M | 235.66 M | 176.23 M |
| 2018 | 12.07 M | -260,188,000 | 283.81 M | 295.75 M | 262.25 M |